UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)
Go back to UCB Announces Publication of Data in Brain Communications Demonstrating Positive Impact of KYGEVVI® (doxecitine and doxribtimine) in Patients with Thymidine Kinase 2 Deficiency (TK2d)| (NYSE: UCB) | Delayed: 33.38 +0.53 (1.61%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $32.85 | 52 Week High | $ | |||
| Open | $32.96 | 52 Week Low | $ | |||
| Day High | $33.40 | P/E | N/A | |||
| Day Low | $32.85 | EPS | $ | |||
| Volume | 1,070,088 | |||||
| UCB Unsponsored ADR (AMEX: UCBJY) | Delayed: 141.43 -1.7 (1.19%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $143.13 | 52 Week High | $46.25 | |||
| Open | $139.93 | 52 Week Low | $32.74 | |||
| Day High | $141.79 | P/E | N/A | |||
| Day Low | $139.54 | EPS | $0.00 | |||
| Volume | 39,487 | |||||
